Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (100.0%)Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Phase 4
Withdrawn
- Conditions
- Kidney FailureKidney DiseasesHepatitis C
- Interventions
- Drug: glecaprevir/pibrentasvir tablets
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Raymond T. Chung, MD
- Registration Number
- NCT03623568
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
Phase 4
Withdrawn
- Conditions
- Cardiac Transplant DisorderHepatitis C
- Interventions
- Drug: Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Raymond T. Chung, MD
- Registration Number
- NCT03026023
- Locations
- 🇺🇸
Masschusetts General Hospital, Boston, Massachusetts, United States
News
No news found